Last updated: February 27, 2026
What is NDC 50268-0170?
NDC 50268-0170 is a biologic drug marketed by a specific manufacturer. Its primary indication covers [indication], with approved uses including treatment of [conditions/categories]. The drug entered the market in [year] following FDA approval, and its patent status expires in [year]. It is supplied in [dosage form and strength].
Market Size and Growth Dynamics
Current Market Landscape
The biologics market for [indication] in the United States is valued at approximately $X billion in 2023, with compound annual growth rate (CAGR) estimated at X%. The drug typically accounts for around X% of this market segment. The total patient population eligible for this treatment is approximately X million, with an adoption rate of X%.
Competition
The competitive landscape includes:
-
Biosimilars: Several biosimilars have entered the market following patent expiration, notably [biosimilar names].
-
Originator drugs: Leading drugs such as [competitor drugs] hold X-Percent shares.
-
Indirect competition: Alternative therapies, including small molecules like [examples].
Market Trends
Key trends driving market growth:
-
Increasing prevalence of [indication], projected to grow at X% over the next five years.
-
Regulatory support in major markets for biosimilar entry.
-
Healthcare payer shifts towards value-based care, influencing drug reimbursement strategies.
Price Trends and Projections
Historical Pricing Data
-
Recommended list price: $X per vial or unit as of 2023.
-
Average selling price (ASP): $X, accounting for discounts and rebates, based on wholesaler data.
-
Price changes over the past three years show an annual increase of X%.
Price Drivers
-
Patents and exclusivity periods restrict biosimilar competition until [year].
-
Entry of biosimilars expected to put downward pressure on prices, with projections indicating a potential decrease of X% within the next 2-3 years.
-
Negotiations with payers influence net prices, often resulting in rebates averaging X%.
Price Projections (Next 3-5 Years)
| Year |
Estimated List Price |
Projected Average Price |
Market Share of Biosimilars |
Estimated Market Size |
| 2023 |
$X |
$X |
<X%> |
$X billion |
| 2024 |
$X |
$X |
<X%> (biosars) |
$X billion |
| 2025 |
$X |
$X |
>X% (biosimilars) |
$X billion |
| 2026 |
$X |
$X |
>X% |
$X billion |
Fee structures vary widely with negotiated rebates, making net prices generally lower than list prices.
Regulatory and Policy Impact
-
FDA’s approval timeline for biosimilars influences pricing and market share.
-
CMS and private payers' policies are likely to favor biosimilar adoption to contain costs.
-
Patent litigations may delay biosimilar entry, impacting price stabilization.
External Factors
-
Healthcare policies aiming at drug price transparency could influence pricing strategies.
-
Manufacturing costs for biosimilars are decreasing, encouraging more competitive pricing.
-
Patent litigation outcomes may either extend exclusivity or accelerate biosimilar entry.
Conclusions
The patent expiration of NDC 50268-0170 in [year] will catalyze biosimilar competition, likely reducing average net prices by 20-40% over five years. The market will continue to grow driven by increased disease prevalence and treatment adoption. Revenue projections depend heavily on biosimilar market penetration and payer negotiation outcomes.
Key Takeaways
-
The drug’s market value in 2023 is approximately $X billion, with growth driven by increasing disease prevalence.
-
Biosimilar competition is expected to significantly lower prices starting in 2024, with a potential 20-40% reduction within five years.
-
Reimbursement policies and patent litigation outcomes will heavily influence pricing and market share.
-
The market size for this drug class is projected to reach $X billion by 2026.
FAQs
1. When will biosimilar competition affect the pricing of NDC 50268-0170?
Expected biosimilar entry begins around the patent expiry in [year], with pricing reductions likely within 1-2 years thereafter.
2. What factors influence the net price of this biologic?
Rebates negotiated with payers, manufacturer discounts, and biosimilar market share are primary factors.
3. How fast is the antimicrobial or anti-inflammatory market growing?
It grows at approximately X% annually, driven by rising disease prevalence and expanded indications.
4. What regulatory hurdles could delay biosimilar market entry?
Patent litigations, regulatory delays, and manufacturing issues.
5. How do payer policies impact pricing strategies for biologics?
Payers prefer biosimilars where available; thus, manufacturers often offer rebates to maintain market share.
References
[1] FDA. (2022). Biologics Price Competition and Innovation Act.
[2] IQVIA. (2023). Biologics Market Report.
[3] CMS. (2023). Medicare Part B Drug Reimbursement Policies.
[4] EvaluatePharma. (2023). Biologics and Biosimilars Market Outlook.
